Souhaitez-vous accéder aux communiqués récents ?

Urteste S.A. launches European multicenter clinical study of the Panuri test Gdańsk, Poland – 6 November 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development...

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic...

Galera Therapeutics Announces Acquisition of Avasopasem and the Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board